Jessica S Donington1, Rebecca Paulus2, Martin J Edelman3, Mark J Krasna4, Quynh-Thu Le5, Mohan Suntharalingam6, Billy W Loo5, Chen Hu7, Jeffrey D Bradley8. 1. Department of Department of Surgery, University of Chicago Medicine and Biologic Sciences, Chicago, Ill. Electronic address: jdonington@uchicago.edu. 2. Department of Department of Surgery, University of Chicago Medicine and Biologic Sciences, Chicago, Ill. 3. Division of Medical Oncology, Department of Medicine, University of Maryland Medical Center, Baltimore, Md. 4. Department of Surgery, Jersey Shore University Medical Center, Neptune City, NJ. 5. Department of Radiation Oncology, Stanford Cancer Institute, Stanford, Calif. 6. Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Md. 7. NRG Oncology Statistics and Data Management Center, Philadelphia, Pa; Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Md. 8. Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Ga.
Abstract
OBJECTIVE: Concern exists regarding surgery after thoracic radiation. We aimed to assess early results of anatomic resection following induction therapy with platinum-based chemotherapy and full-dose thoracic radiation for resectable N2+ stage IIIA non-small cell lung cancer. METHODS: Two prospective trials were recently conducted by NRG Oncology in patients with resectable N2+ stage IIIA non-small cell lung cancer with the primary end point of mediastinal node sterilization following concurrent full-dose chemoradiotherapy (Radiation Therapy Oncology Group trials 0229 and 0839). All surgeons demonstrated postinduction resection expertise. Induction consisted of weekly carboplatin (area under the curve, 2.0) and paclitaxel (50 mg/m2) and concurrent thoracic radiation 60 Gy (0839)/61.2 Gy (0229) in 30 fractions. Patients in study 0839 were randomized 2:1 to weekly panitumumab + chemoradiotherapy or chemoradiotherapy alone during induction. Primary results were similar in all treatment arms and reported previously. Short-term surgical outcomes are reported here. RESULTS: One hundred twenty-six patients enrolled; 93 (74%) had anatomic resection, 77 underwent lobectomy, and 16 underwent extended resection. Microscopically margin-negative resections occurred in 85 (91%). Fourteen (15%) resections were attempted minimally invasively, including 2 converted without event. Grade 3 or 4 surgical adverse events were reported in 26 (28%), 30-day mortality in 4 (4%) and 90-day mortality in 5 (5%). Patients undergoing extended resection experienced similar rates of grade 3 or 4 adverse events (odds ratio, 0.95; 95% confidence interval, 0.42-3.8) but higher 30-day (1.3% vs 18.8%) (odds ratio, 17.54; 95% confidence interval, 1.75-181.8) and 90-day mortality (2.6% vs 18.8%) (odds ratio, 8.65; 95% confidence interval, 1.3-56.9). CONCLUSIONS: Lobectomy was performed safely following full-dose concurrent chemoradiotherapy in these multi-institutional prospective trials; however, increased mortality was noted with extended resections.
OBJECTIVE: Concern exists regarding surgery after thoracic radiation. We aimed to assess early results of anatomic resection following induction therapy with platinum-based chemotherapy and full-dose thoracic radiation for resectable N2+ stage IIIA non-small cell lung cancer. METHODS: Two prospective trials were recently conducted by NRG Oncology in patients with resectable N2+ stage IIIA non-small cell lung cancer with the primary end point of mediastinal node sterilization following concurrent full-dose chemoradiotherapy (Radiation Therapy Oncology Group trials 0229 and 0839). All surgeons demonstrated postinduction resection expertise. Induction consisted of weekly carboplatin (area under the curve, 2.0) and paclitaxel (50 mg/m2) and concurrent thoracic radiation 60 Gy (0839)/61.2 Gy (0229) in 30 fractions. Patients in study 0839 were randomized 2:1 to weekly panitumumab + chemoradiotherapy or chemoradiotherapy alone during induction. Primary results were similar in all treatment arms and reported previously. Short-term surgical outcomes are reported here. RESULTS: One hundred twenty-six patients enrolled; 93 (74%) had anatomic resection, 77 underwent lobectomy, and 16 underwent extended resection. Microscopically margin-negative resections occurred in 85 (91%). Fourteen (15%) resections were attempted minimally invasively, including 2 converted without event. Grade 3 or 4 surgical adverse events were reported in 26 (28%), 30-day mortality in 4 (4%) and 90-day mortality in 5 (5%). Patients undergoing extended resection experienced similar rates of grade 3 or 4 adverse events (odds ratio, 0.95; 95% confidence interval, 0.42-3.8) but higher 30-day (1.3% vs 18.8%) (odds ratio, 17.54; 95% confidence interval, 1.75-181.8) and 90-day mortality (2.6% vs 18.8%) (odds ratio, 8.65; 95% confidence interval, 1.3-56.9). CONCLUSIONS: Lobectomy was performed safely following full-dose concurrent chemoradiotherapy in these multi-institutional prospective trials; however, increased mortality was noted with extended resections.
Authors: Miklos Pless; Roger Stupp; Hans-Beat Ris; Rolf A Stahel; Walter Weder; Sandra Thierstein; Marie-Aline Gerard; Alexandros Xyrafas; Martin Früh; Richard Cathomas; Alfred Zippelius; Arnaud Roth; Milorad Bijelovic; Adrian Ochsenbein; Urs R Meier; Christoph Mamot; Daniel Rauch; Oliver Gautschi; Daniel C Betticher; René-Olivier Mirimanoff; Solange Peters Journal: Lancet Date: 2015-08-11 Impact factor: 79.321
Authors: David J Sher; Mary Jo Fidler; Christopher W Seder; Michael J Liptay; Matthew Koshy Journal: Int J Radiat Oncol Biol Phys Date: 2015-03-30 Impact factor: 7.038
Authors: Rafael Santana-Davila; Kiran Devisetty; Aniko Szabo; Rodney Sparapani; Carlos Arce-Lara; Elizabeth M Gore; Amy Moran; Christina D Williams; Michael J Kelley; Jeffrey Whittle Journal: J Clin Oncol Date: 2014-11-24 Impact factor: 44.544
Authors: Mohan Suntharalingam; Rebecca Paulus; Martin J Edelman; Mark Krasna; Whitney Burrows; Elizabeth Gore; Lynn D Wilson; Hak Choy Journal: Int J Radiat Oncol Biol Phys Date: 2012-04-28 Impact factor: 7.038
Authors: Robert James Cerfolio; Ayesha S Bryant; Virginia L Jones; Robert Michael Cerfolio Journal: Eur J Cardiothorac Surg Date: 2009-02-23 Impact factor: 4.191
Authors: Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox Journal: Lancet Date: 2009-07-24 Impact factor: 79.321
Authors: Wilfried Ernst Erich Eberhardt; Christoph Pöttgen; Thomas Christoph Gauler; Godehard Friedel; Stefanie Veit; Vanessa Heinrich; Stefan Welter; Wilfried Budach; Werner Spengler; Martin Kimmich; Berthold Fischer; Heinz Schmidberger; Dirk De Ruysscher; Claus Belka; Sebastian Cordes; Rodrigo Hepp; Diana Lütke-Brintrup; Nils Lehmann; Martin Schuler; Karl-Heinz Jöckel; Georgios Stamatis; Martin Stuschke Journal: J Clin Oncol Date: 2015-11-02 Impact factor: 44.544
Authors: Kyle Wang; Michael J Eblan; Allison M Deal; Matthew Lipner; Timothy M Zagar; Yue Wang; Panayiotis Mavroidis; Carrie B Lee; Brian C Jensen; Julian G Rosenman; Mark A Socinski; Thomas E Stinchcombe; Lawrence B Marks Journal: J Clin Oncol Date: 2017-01-23 Impact factor: 50.717
Authors: Kevin X Liu; Kailan Sierra-Davidson; Kevin Tyan; Lawrence T Orlina; J Paul Marcoux; Benjamin H Kann; David E Kozono; Raymond H Mak; Abby White; Lisa Singer Journal: Radiother Oncol Date: 2021-10-22 Impact factor: 6.280